425: Graphite Bio Announces Special Dividend in Connection with Lenz Therapeutics Merger

Graphite Bio declares a special cash dividend of approximately $1.03 per share for stockholders in connection with its proposed merger with Lenz Therapeutics, pending stockholder approval and merger completion.

Summary

• Graphite Bio has announced a special cash dividend to its stockholders in connection with the proposed merger with Lenz Therapeutics.
• The dividend is estimated to be $1.03 per share of Graphite's common stock.
• The record date for the dividend is March 18, 2024, and the payment date is March 21, 2024.
• The exact amount of the dividend will be calculated after deducting certain cash amounts as set forth in the Merger Agreement, and will not exceed $60 million, subject to adjustments.
• Payment of the dividend is contingent upon the closing of the merger, which is subject to stockholder approval and other closing conditions.
• A special meeting of Graphite's stockholders is scheduled for March 14, 2024, to vote on the merger, with closing expected after market close on March 21, 2024, assuming approval and satisfaction of all conditions.

Sentiment

Score: 7

Explanation: The announcement of a special dividend is generally positive for shareholders. However, the sentiment is tempered by the risks associated with the merger and the uncertainties surrounding the combined company's future.

Positives

• Stockholders will receive a special cash dividend of approximately $1.03 per share if the merger with Lenz Therapeutics is completed.
• The announcement provides clarity on the financial benefits stockholders can expect from the merger.
• The merger with Lenz Therapeutics is expected to create a combined company focused on developing innovative therapies to improve vision.

Negatives

• The special dividend is contingent on the successful completion of the merger, which is not guaranteed.
• The exact amount of the dividend is subject to adjustments, which could result in a lower payout than the estimated $1.03 per share.
• Graphite Bio discontinued development of its lead product candidate for sickle cell disease in February 2023.

Risks

• The merger is subject to stockholder approval and other closing conditions, which may not be met.
• There are risks associated with managing operating expenses and expenses related to the merger pending closing.
• Failure to obtain required governmental approvals could delay or prevent the merger.
• Adjustments to the exchange ratio could impact the ownership structure of the combined company.
• Unexpected costs or adverse reactions to business relationships could arise from the merger.
• There are uncertainties associated with Lenz's product candidates, including clinical development and regulatory approval risks.
• The combined company may be unable to obtain sufficient additional capital to advance product candidates.
• The private financing may not be consummated upon the closing of the merger.
• Graphite stockholders may receive more or less of the cash dividend than is currently anticipated.

Future Outlook

The combined company will focus on developing and commercializing innovative therapies to improve vision, with Lenz's product candidates being the primary focus.

Management Comments

• Graphite Bio's Board of Directors has declared a special dividend in connection with the previously announced merger with Lenz Therapeutics.

Industry Context

The merger reflects a trend in the biotech industry where companies with strong cash positions acquire companies with promising clinical assets to diversify their pipelines and create shareholder value.

Comparison to Industry Standards

• Special dividends are often used in mergers to distribute excess cash to shareholders, similar to actions taken by other biotech companies during acquisitions.
• The focus on ophthalmology by the combined company aligns with the growing market for vision-related therapies, comparable to companies like Ocular Therapeutix and REGENXBIO who are also developing innovative treatments for eye diseases.

Stakeholder Impact

• Shareholders will receive a special dividend if the merger is completed.
• Employees of both Graphite Bio and Lenz Therapeutics may experience changes as a result of the merger.
• The merger could lead to the development of new therapies that benefit patients with vision impairments.

Next Steps

• Graphite's stockholders will vote on the proposed merger at a special meeting on March 14, 2024.
• If approved, the merger is expected to close after market close on March 21, 2024.
• The special dividend will be paid to stockholders of record as of March 18, 2024, on March 21, 2024, contingent upon the merger closing.

Key Dates